SONNET BIOTHERAPEUTICS HOLDI (SONN) Stock Price, Quote, News and Overview
NASDAQ:SONN - Nasdaq - US83548R4020 - Common Stock - Currency: USD
SONN Quote, Performance and Key Statistics
NASDAQ:SONN (6/10/2025, 3:09:05 PM)
1.1812
-0.04 (-3.18%)
The current stock price of SONN is 1.1812 USD. In the past month the price decreased by -4.45%. In the past year, price decreased by -90.73%.
SONN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.52 | 336.06B | ||
| AMGN | AMGEN INC | 14.14 | 157.82B | ||
| GILD | GILEAD SCIENCES INC | 14.41 | 138.72B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 116.48B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.91 | 56.96B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.65B | ||
| ARGX | ARGENX SE - ADR | 100.82 | 35.40B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.76 | 28.59B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.77B | ||
| NTRA | NATERA INC | N/A | 22.52B | ||
| BIIB | BIOGEN INC | 8.58 | 19.90B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.56B |
Related stock screener links
About SONN
Company Profile
Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. The company is headquartered in Princeton, New Jersey and currently employs 13 full-time employees. The company went IPO on 2005-07-27. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The firm's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The firm is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).
Company Info
SONNET BIOTHERAPEUTICS HOLDI
100 Overlook Center, Suite 102
Princeton NEW JERSEY 08540 US
CEO: Pankaj Mohan
Employees: 13
Phone: 16093752227
SONNET BIOTHERAPEUTICS HOLDI / SONN FAQ
What is the stock price of SONNET BIOTHERAPEUTICS HOLDI today?
The current stock price of SONN is 1.1812 USD. The price decreased by -3.18% in the last trading session.
What is the ticker symbol for SONNET BIOTHERAPEUTICS HOLDI stock?
The exchange symbol of SONNET BIOTHERAPEUTICS HOLDI is SONN and it is listed on the Nasdaq exchange.
On which exchange is SONN stock listed?
SONN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SONNET BIOTHERAPEUTICS HOLDI stock?
7 analysts have analysed SONN and the average price target is 20.4 USD. This implies a price increase of 1627.06% is expected in the next year compared to the current price of 1.1812. Check the SONNET BIOTHERAPEUTICS HOLDI stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SONNET BIOTHERAPEUTICS HOLDI worth?
SONNET BIOTHERAPEUTICS HOLDI (SONN) has a market capitalization of 3.74M USD. This makes SONN a Nano Cap stock.
How many employees does SONNET BIOTHERAPEUTICS HOLDI have?
SONNET BIOTHERAPEUTICS HOLDI (SONN) currently has 13 employees.
What are the support and resistance levels for SONNET BIOTHERAPEUTICS HOLDI (SONN) stock?
SONNET BIOTHERAPEUTICS HOLDI (SONN) has a resistance level at 1.25. Check the full technical report for a detailed analysis of SONN support and resistance levels.
Should I buy SONNET BIOTHERAPEUTICS HOLDI (SONN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SONN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SONN, evaluating the profitability, health, valuation and growth aspects
- SONNET BIOTHERAPEUTICS HOLDI (SONN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SONNET BIOTHERAPEUTICS HOLDI (SONN) Sales and EPS estimates to see what analysts future expectations are.
- SONNET BIOTHERAPEUTICS HOLDI (SONN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SONNET BIOTHERAPEUTICS HOLDI (SONN) Insider and Institutional Ownership to learn about the owners and their transactions.
- SONNET BIOTHERAPEUTICS HOLDI (SONN) Stock Chart to make your own analysis
- SONNET BIOTHERAPEUTICS HOLDI (SONN) Latest news and press-releases to stay up to date.
Does SONNET BIOTHERAPEUTICS HOLDI (SONN) stock pay dividends?
SONN does not pay a dividend.
When does SONNET BIOTHERAPEUTICS HOLDI (SONN) report earnings?
SONNET BIOTHERAPEUTICS HOLDI (SONN) will report earnings on 2025-08-12.
What is the Price/Earnings (PE) ratio of SONNET BIOTHERAPEUTICS HOLDI (SONN)?
SONNET BIOTHERAPEUTICS HOLDI (SONN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.88).
What is the Short Interest ratio of SONNET BIOTHERAPEUTICS HOLDI (SONN) stock?
The outstanding short interest for SONNET BIOTHERAPEUTICS HOLDI (SONN) is 3.14% of its float. Check the ownership tab for more information on the SONN short interest.
SONN Technical Analysis
SONN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SONN. The financial health of SONN is average, but there are quite some concerns on its profitability.
SONN Financial Highlights
Over the last trailing twelve months SONN reported a non-GAAP Earnings per Share(EPS) of -11.88. The EPS increased by 71.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -346.31% | ||
| ROE | -2006.04% | ||
| Debt/Equity | 0 |
SONN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to SONN. The Buy consensus is the average rating of analysts ratings from 7 analysts.